The innovator and generic pharmaceutical industries are both urging the US FDA to take a clear-cut, simplistic approach to granting orphan drug designation and exclusivity for tissue-agnostic cancer therapies, but agency officials suggest it may not be as easy as industry would like.
At a May 9 meeting, a panel of FDA staff, industry representatives, clinicians and patient advocates debated the appropriateness of...






